This article is part of the network’s archive of useful research information. This article is closed to new comments due to inactivity. We welcome new content which can be done by submitting an article for review or take part in discussions in an open topic or submit a blog post to take your discussions online.
Addis Ababa, 13 July 2017 – The second and final workshop of the inaugural Clinical Research During Outbreaks (CREDO) course was held in Addis Ababa on 12-13 July 2017. The workshop gathered 18 participants from Côte d’Ivoire, Ethiopia, Ghana and Uganda.
These participants had attended the first workshop in March 2017 in Entebbe, Uganda, and completed online training modules between March and July. The teams also contributed to the development of the CREDO course, by pilot-testing and helping refine the materials and teaching approach.
CREDO is a training curriculum developed to strengthen the capacity of research teams in low- and middle-income countries to conduct clinical research on emerging and epidemic-prone infectious diseases. It blends face-to-face teaching and on-line training modules.
At the final workshop the teams participated also in two outbreak research scenarios, where they developed and presented their design for a theoretical observational clinical study and a theoretical clinical trial. For the clinical trial scenario, facilitators played the roles of statistical, scientific, and ethical reviewers, and community and government representatives.
The experience and evaluation of the initial CREDO course will be used to create the final CREDO product. Materials will then be made available for stakeholders and potential new partners who wish to ensure wider, long-term accessibility to this training resource. CREDO has been endorsed by the African Academy of Sciences.
The programme is being developed by the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC), TDR, and the UK Public Health Rapid Support team .
For more information, contact:
Piero Olliaro at TDR (firstname.lastname@example.org) or
Peter Horby at the University of Oxford (email@example.com)
- Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19
- What is the recovery rate and risk of long-term consequences following a diagnosis of COVID-19? - A harmonised, global longitudinal observational study
- An open-label, randomized, non-inferiority trial of the efficacy and safety of ciprofloxacin versus streptomycin + ciprofloxacin in the treatment of bubonic plague (IMASOY): study protocol for a rando